Quarterly ResultMay 12, 2026, 04:23 PM
Atara Biotherapeutics Reports Q1 Net Loss $(4.1M); Going Concern Warning
AI Summary
Atara Biotherapeutics reported a significant net loss of $(4.1) million for Q1 2026, a sharp decline from a $38.0 million net income in Q1 2025, with commercialization revenue plummeting to $516K from $98.1 million. The company issued a going concern warning, stating existing capital is insufficient for the next 12 months. Strategic shifts include transferring all manufacturing, clinical, development, and regulatory responsibilities for tab-cel to Pierre Fabre, and amending the HCRx agreement to extend a $9.0 million payment due date.
Key Highlights
- Issued a going concern warning, citing insufficient capital for the next 12 months.
- Q1 2026 net loss was $(4.1) million, compared to net income of $38.0 million in Q1 2025.
- Commercialization revenue for Q1 2026 decreased to $516K from $98.1 million in Q1 2025.
- Basic loss per common share was $(0.29) in Q1 2026, down from earnings of $3.53 in Q1 2025.
- Net cash used in operating activities significantly reduced to $(3.1) million in Q1 2026 from $(28.1) million in Q1 2025.
- Cash and cash equivalents were $8.4 million as of March 31, 2026.
- Extended $9.0 million HCRx payment due date to January 1, 2028.
- Transferred all tab-cel manufacturing, clinical, development, and regulatory responsibilities to Pierre Fabre.